# Calytrix Bio

> Preclinical biotech developing mutant-CALR-targeting antibodies for myeloproliferative neoplasms; agreed to be acquired by Lilly.

## Why it is interesting

Its November 16, 2026 announced Lilly acquisition carries a maximum contingent consideration of $1.5B, not a disclosed upfront price or completed sale. The lead biparatopic antibody is preclinical; disease-modifying benefit has not been demonstrated in people.

## Profile

- **Latest funding:** Series A (amount undisclosed) (Date not disclosed)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** other
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-16
- **Latest funding investors:** J.P. Morgan Life Sciences Private Capital, Westlake BioPartners

## Key facts

- Lilly acquisition announced Nov 16, 2026 for up to $1.5B; actual upfront cash amount undisclosed.
- Milestone payments depend on future clinical/regulatory progress; the maximum is not guaranteed cash.
- Calytrix lead mCALR biparatopic antibody remains preclinical, not an approved medicine.
- Founded by J.P. Morgan Life Sciences Private Capital in 2025; Series A co-led with Westlake BioPartners and subsequent Series B led by Avoro Ventures, with round amounts not disclosed.

## Funding history

- Series A (amount undisclosed)
  Source: https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html
- Series B (amount undisclosed)
  Source: https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/calytrix-bio
